Mark Hahn
2020 - Verona Pharma plc
In 2020, Mark Hahn earned a total compensation of $18.5M as Chief Financial Officer at Verona Pharma plc.
Compensation breakdown
| Non-Equity Incentive Plan | $275,000 |
|---|---|
| Salary | $229,167 |
| Stock Awards | $17,915,584 |
| Other | $35,047 |
| Total | $18,454,798 |
Hahn received $17.9M in stock awards, accounting for 97% of the total pay in 2020.
Hahn also received $275K in non-equity incentive plan, $229.2K in salary and $35K in other compensation.
Rankings
In 2020, Mark Hahn's compensation ranked 262nd out of 13,090 executives tracked by ExecPay. In other words, Hahn earned more than 98.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 262 out of 13,090 | 98th |
Division Manufacturing | 79 out of 5,617 | 99th |
Major group Chemicals And Allied Products | 23 out of 2,248 | 99th |
Industry group Drugs | 21 out of 1,948 | 99th |
Industry Pharmaceutical Preparations | 12 out of 1,453 | 99th |
Source: SEC filing on March 19, 2021.
Hahn's colleagues
We found three more compensation records of executives who worked with Mark Hahn at Verona Pharma plc in 2020.